PROZ May Serve as a Prognostic Biomarker for Early Hepatocellular Carcinoma

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Cao W, Chen H-D, Yu Y-W, Li N, Chen W-Q. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med. 2021;134(7):783–791. doi:10.1097/CM9.0000000000001474
   Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Wang S, Toy M, Hang Pham TT, So S, Alpini GD. Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the U.S., 2010–2019. PLoS One. 2020;15(9):e0239393. doi:10.1371/journal.pone.0239393
   PubMed Web of Science ®Google Scholar
• Si J, Yu C, Guo Y, et al. Chronic hepatitis B virus infection and total and cause-specific mortality: a Prospective Cohort Study of 0.5 million people. BMJ Open. 2019;9(4):e027696. doi:10.1136/bmjopen-2018-027696
   PubMed Web of Science ®Google Scholar
• Song C, Lv J, Liu Y, et al. Associations between hepatitis B virus infection and risk of all cancer types. JAMA Netw Open. 2019;2(6):e195718. doi:10.1001/jamanetworkopen.2019.5718
   PubMed Web of Science ®Google Scholar
• Signoriello S, Annunziata A, Lama N, et al. Survival after locoregional treatments for hepatocellular carcinoma: a Cohort Study in real-world patients. ScientificWorldJournal. 2012;2012:564706. doi:10.1100/2012/564706
   PubMed Web of Science ®Google Scholar
• Lin CL, Kao JH; Research H. Prevention of hepatitis B virus-related hepatocellular carcinoma. Hepatoma Res. 2021;7(1):9.
   Google Scholar
• Sangiovanni A, Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2016;36:124–129. doi:10.1111/liv.13028
   PubMed Web of Science ®Google Scholar
• Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res. 2020;6. doi:10.20517/2394-5079.2020.42 
   PubMedGoogle Scholar
• Wang T, Zhang KH. New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma. Front Oncol. 2020;10:1316. doi:10.3389/fonc.2020.01316
   PubMed Web of Science ®Google Scholar
• Zhao S, Long M, Zhang X, et al. The diagnostic value of the combination of Golgi protein 73, glypican-3 and alpha-fetoprotein in hepatocellular carcinoma: a diagnostic meta-analysis. Ann Transl Med. 2020;8(8):536. doi:10.21037/atm.2020.02.89
   PubMed Web of Science ®Google Scholar
• Wu M, Liu Z, Li X, Zhang A, Li N. Dynamic changes in serum markers and their utility in the early diagnosis of all stages of hepatitis B-associated hepatocellular carcinoma. Onco Targets Ther. 2020;13:827–840. doi:10.2147/OTT.S229835
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Takayama T, Kurokawa T, et al. Next-generation des-r-carboxy prothrombin for immunohistochemical assessment of vascular invasion by hepatocellular carcinoma. BMC Surg. 2020;20(1):201. doi:10.1186/s12893-020-00862-0
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang ZX, Chen XY, et al. A panel of three biomarkers identified by iTRAQ for the early diagnosis of pancreatic cancer. Proteomics Clin Appl. 2019;13(5):e1800195. doi:10.1002/prca.201800195
   PubMed Web of Science ®Google Scholar
• Li D, Ji Y, Guo J, Guo Q. Upregulated expression of MTFR2 as a novel biomarker predicts poor prognosis in hepatocellular carcinoma by bioinformatics analysis. Future Oncol. 2021;17(24). doi:10.2217/fon-2020-1160
   Web of Science ®Google Scholar
• Liang Y, Ma B, Jiang P, Yang HM. Identification of methylation-regulated differentially expressed genes and related pathways in hepatocellular carcinoma: a study based on TCGA database and bioinformatics analysis. Front Oncol. 2021;11:636093. doi:10.3389/fonc.2021.636093
   PubMed Web of Science ®Google Scholar
• Shang Y, Pan XY, Ding CP, et al. [Clinical significance of protein Z detection in patients with malignant tumors]. Chinese Journal of Cancer. 2005;24(9):1144–1147. Chinese.
   Google Scholar
• Galar M, Piszcz J, Bolkun L, Szumowska A, Kloczko J. Protein Z concentrations in patients with acute leukemia. Clin Appl Thromb Hemost. 2012;18(5):542–545. doi:10.1177/1076029611429784
   PubMed Web of Science ®Google Scholar
• Wojtukiewicz MZ, Sierko E, Kisiel W. The role of hemostatic system inhibitors in malignancy. Semin Thromb Hemost. 2007;33(7):621–642. doi:10.1055/s-2007-991530
   PubMed Web of Science ®Google Scholar
• Sierko E, Wojtukiewicz MZ, Zimnoch L, Tokajuk P, Kisiel W. Protein Z is present in human breast cancer tissue. Int J Hematol. 2011;93(5):681–683. doi:10.1007/s12185-011-0846-3
   PubMed Web of Science ®Google Scholar
• Sierko E, Wojtukiewicz MZ, Ostrowska-Cichocka K, Zimnoch L. Protein Z-dependent protease inhibitor (ZPI) is present in loco in human breast cancer tissue. Thromb Haemost. 2010;104(1):183–185. doi:10.1160/TH09-09-0666
   PubMed Web of Science ®Google Scholar
• Sierko E, Zabrocka E, Ostrowska-Cichocka K, Tokajuk P, Zimnoch L, Wojtukiewicz MZ. Co-localization of coagulation factor X and its inhibitory system, PZ/ ZPI, in human endometrial cancer tissue. In Vivo (Brooklyn). 2019;33(3):771–776. doi:10.21873/invivo.11538
   Web of Science ®Google Scholar
• Sierko E, Wojtukiewicz MZ, Zimnoch L, Tokajuk P, Ostrowska-Cichocka K, Kisiel W. Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer. Ann Hematol. 2014;93(5):779–784. doi:10.1007/s00277-013-1941-8
   PubMed Web of Science ®Google Scholar
• Sierko E, Wojtukiewicz MZ, Zimnoch L, Tokajuk P, Ostrowska-Cichocka K, Kisiel W. Co-localization of protein Z, protein Z-dependent protease inhibitor and coagulation factor X in human colon cancer tissue: implications for coagulation regulation on tumor cells. Thromb Res. 2012;129(4):e112–118. doi:10.1016/j.thromres.2011.10.027
   PubMed Web of Science ®Google Scholar
• Sierko E, Wojtukiewicz MZ, Zimnoch L, et al. Protein Z/protein Z-dependent protease inhibitor system in human non-small-cell lung cancer tissue. Thromb Res. 2012;129(4):e92–96. doi:10.1016/j.thromres.2011.09.005
   PubMed Web of Science ®Google Scholar
• Wang H, Huang F, Pan XY, et al. Quantification of protein Z expression in lung adenocarcinoma tissues and cells. Springerplus. 2016;5(1):1046. doi:10.1186/s40064-016-2610-x
   PubMedGoogle Scholar
• Li Z, Xu J, Cui H, Song J, Chen J, Wei J. Bioinformatics analysis of key biomarkers and potential molecular mechanisms in hepatocellular carcinoma induced by hepatitis B virus. Medicine (Baltimore). 2020;99(20):e20302. doi:10.1097/MD.0000000000020302
   PubMed Web of Science ®Google Scholar
• Neumann O, Kesselmeier M, Geffers R, et al. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology. 2012;56(5):1817–1827. doi:10.1002/hep.25870
   PubMed Web of Science ®Google Scholar
• Vasse M. The protein Z/protein Z-dependent protease inhibitor complex. Systemic or local control of coagulation? Hamostaseologie. 2011;31(3):155–158, 160–154. doi:10.5482/ha-1161
   Web of Science ®Google Scholar